NCT04071639 is a Phase 1 clinical trial of Haloperidol 2Mg Tab in Huntington Disease, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who is sponsoring NCT04071639?

NCT04071639 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What drugs are being tested in NCT04071639?

Interventions in NCT04071639: Haloperidol 2Mg Tab, Risperidone 1Mg Tab, Zoloft 50Mg Tablet, Idebenone, Deutetrabenazine Oral Tablet [Austedo].

What condition does NCT04071639 study?

NCT04071639 studies Huntington Disease.

Is NCT04071639 still recruiting?

NCT04071639 is currently status unknown. Last updated 2 April 2021.

Last reviewed 2021-04-02 · How we verify

NCT04071639

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Symptomatic Therapy for Patients With Huntington's Disease

Status unknown Phase 1 Last updated 2 April 2021

What this trial tests

Phase 1 trial testing Haloperidol 2Mg Tab in Huntington Disease in 60 participants. Status unknown.

Timeline

12 March 2020

Primary endpoint
31 December 2024

31 December 2024

Quick facts

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	12 March 2020
Primary completion	31 December 2024
Estimated completion	31 December 2024
Sites	1 location across China

Drugs / interventions tested

Haloperidol 2Mg Tab — full drug profile →
Risperidone 1Mg Tab — full drug profile →
Zoloft 50Mg Tablet — full drug profile →
Idebenone (IDEBENONE) — full drug profile →
Deutetrabenazine Oral Tablet [Austedo] — full drug profile →

Conditions studied

Huntington Disease — all drugs for Huntington Disease →

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

Eligibility, any sex, with Huntington Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Based on the previous symptomatic treatment of Chinese HD patients, this study intends to further optimize the treatment regimen of Chinese HD patients so as to further improve the prognosis of patients.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

New Avenues for the Treatment of Huntington's Disease.
Kim A, Lalonde K, Truesdell A, Gomes Welter P, et al · · 2021 · cited 130× · PMID 34445070 · DOI 10.3390/ijms22168363
From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington's Disease Research.
Jiang A, Handley RR, Lehnert K, Snell RG. · · 2023 · cited 88× · PMID 37629202 · DOI 10.3390/ijms241613021
Huntington's Disease Clinical Trials Corner: March 2024.
Estevez-Fraga C, Tabrizi SJ, Wild EJ. · · 2024 · cited 31× · PMID 38489195 · DOI 10.3233/jhd-240017
Huntington's Disease Clinical Trials Corner: August 2023.
Estevez-Fraga C, Tabrizi SJ, Wild EJ. · · 2023 · cited 22× · PMID 37483021 · DOI 10.3233/jhd-239001
Latest advances on new promising molecular-based therapeutic approaches for Huntington's disease.
Cheng Y, Zhang S, Shang H. · · 2024 · cited 13× · PMID 38779119 · DOI 10.2478/jtim-2023-0142
Targeting 5-HT Is a Potential Therapeutic Strategy for Neurodegenerative Diseases.
Xing C, Chen H, Bi W, Lei T, et al · · 2024 · cited 8× · PMID 39769209 · DOI 10.3390/ijms252413446
Huntington's disease clinical trials update: March 2025.
Farag M, Tabrizi SJ, Wild EJ. · · 2025 · cited 7× · PMID 40302443 · DOI 10.1177/18796397251337000
Neuro-Immune Crosstalk: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets.
Guo X, Liu H, Song YJ, Wang JH, et al · · 2026 · cited 2× · PMID 41583906 · DOI 10.1002/mco2.70497

Verify or expand the search:

Other recruiting trials for Huntington Disease

Currently open trials in the same condition.

NCT07326709 — A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease · Phase 3 · recruiting
NCT07253038 — Evaluation of Three Tests to Assess Social Cognition in Huntington Disease · recruiting
NCT06774443 — Hinting Task for Huntington's Disease · recruiting
NCT06546488 — Cognitive Assessment Tools for Huntington's Disease. · recruiting
NCT07010705 — Digital Measures for Clinical Trial Endpoints in Huntington's Disease · recruiting

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04071639 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
Last refreshed: 2 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04071639.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing